<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">20722</article-id><article-id pub-id-type="doi">10.7554/eLife.20722</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-61848"><name><surname>Clarke</surname><given-names>Paul Andrew</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9342-1290</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-68273"><name><surname>Ortiz-Ruiz</surname><given-names>Maria-Jesus</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-75743"><name><surname>TePoele</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-68275"><name><surname>Adeniji-Popoola</surname><given-names>Olajumoke</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-68276"><name><surname>Box</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-68277"><name><surname>Court</surname><given-names>Will</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-75373"><name><surname>Czasch</surname><given-names>Stefanie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-68278"><name><surname>El Bawab</surname><given-names>Samer</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-68279"><name><surname>Esdar</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-68280"><name><surname>Ewan</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-68281"><name><surname>Gowan</surname><given-names>Sharon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-68282"><name><surname>De Haven Brandon</surname><given-names>Alexis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf12"/></contrib><contrib contrib-type="author" id="author-68283"><name><surname>Hewitt</surname><given-names>Phllip</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf13"/></contrib><contrib contrib-type="author" id="author-68284"><name><surname>Hobbs</surname><given-names>Stephen M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf14"/></contrib><contrib contrib-type="author" id="author-68285"><name><surname>Kaufmann</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf15"/></contrib><contrib contrib-type="author" id="author-68286"><name><surname>Mallinger</surname><given-names>Aur√©lie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf16"/></contrib><contrib contrib-type="author" id="author-68287"><name><surname>Raynaud</surname><given-names>Florence</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf17"/></contrib><contrib contrib-type="author" id="author-68288"><name><surname>Roe</surname><given-names>Toby</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf18"/></contrib><contrib contrib-type="author" id="author-68289"><name><surname>Rohdich</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf19"/></contrib><contrib contrib-type="author" id="author-68290"><name><surname>Schiemann</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf20"/></contrib><contrib contrib-type="author" id="author-68291"><name><surname>Simon</surname><given-names>Stephanie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf21"/></contrib><contrib contrib-type="author" id="author-68292"><name><surname>Schneider</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf22"/></contrib><contrib contrib-type="author" id="author-68443"><name><surname>Valenti</surname><given-names>Melanie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf23"/></contrib><contrib contrib-type="author" id="author-75374"><name><surname>Weigt</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf24"/></contrib><contrib contrib-type="author" id="author-68321"><name><surname>Blagg</surname><given-names>Julian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf25"/></contrib><contrib contrib-type="author" id="author-68322"><name><surname>Blaukat</surname><given-names>Andree</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf26"/></contrib><contrib contrib-type="author" corresp="yes" id="author-68323"><name><surname>Dale</surname><given-names>Trevor C</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-68324"><name><surname>Eccles</surname><given-names>Suzanne A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf27"/></contrib><contrib contrib-type="author" id="author-68325"><name><surname>Hecht</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf28"/></contrib><contrib contrib-type="author" id="author-68326"><name><surname>Urbahns</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf29"/></contrib><contrib contrib-type="author" corresp="yes" id="author-45430"><name><surname>Workman</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor3">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf30"/></contrib><contrib contrib-type="author" corresp="yes" id="author-68327"><name><surname>Wienke</surname><given-names>Dirk</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor4">*</xref><xref ref-type="fn" rid="conf31"/></contrib><aff id="aff1"><institution content-type="dept">Cancer Research UK Cancer Therapeutics Unit</institution>, <institution>The Institute of Cancer Research</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution>Merck KGaA</institution>, <addr-line><named-content content-type="city">Darmstadt</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><institution content-type="dept">School of Bioscience</institution>, <institution>Cardiff University</institution>, <addr-line><named-content content-type="city">Cardiff</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1065"><name><surname>Cravatt</surname><given-names>Benjamin F</given-names></name><role>Reviewing editor</role><aff><institution>The Scripps Research Institute</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>paul.clarke@icr.ac.uk</email> (PC);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>daletc@cardiff.ac.uk</email> (TD);</corresp><corresp id="cor3"><label>*</label>For correspondence: <email>paul.workman@icr.ac.uk</email> (PW);</corresp><corresp id="cor4"><label>*</label>For correspondence: <email>dirk.wienke@merckgroup.com</email> (DW);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>09</day><month>12</month><year>2016</year></pub-date><volume>5</volume><elocation-id>e20722</elocation-id><history><date date-type="received"><day>21</day><month>08</month><year>2016</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2016</year></date></history><permissions><copyright-statement>¬© 2016, Clarke et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Clarke et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-20722-v1.pdf"/><abstract><p>Mediator-associated kinases CDK8/19 are context-dependent drivers or suppressors of tumorigenesis. Their inhibition is predicted to have pleiotropic effects, but it is unclear whether this will impact on the clinical utility of CDK8/19 inhibitors. We discovered two series of potent chemical probes with high selectivity for CDK8/19. Despite pharmacodynamic evidence for robust on-target activity, the compounds exhibited modest, though significant, efficacy against human tumor lines and patient-derived xenografts. Altered gene expression was consistent with CDK8/19 inhibition, including profiles associated with super-enhancers, immune and inflammatory responses and stem cell function. In a mouse model expressing oncogenic beta-catenin, treatment shifted cells within hyperplastic intestinal crypts from a stem cell to a transit amplifying phenotype. In two species, neither probe was tolerated at therapeutically-relevant exposures. The complex nature of the toxicity observed with two structurally-differentiated chemical series is consistent with on-target effects posing significant challenges to the clinical development of CDK8/19 inhibitors.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C309/A11566, C368/A6743, A368/A7990</award-id><principal-award-recipient><name><surname>Workman</surname><given-names>Paul</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007913</institution-id><institution>Breast Cancer Now</institution></institution-wrap></funding-source><award-id>2008MayPR16</award-id><principal-award-recipient><name><surname>Dale</surname><given-names>Trevor C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Paul Andrew Clarke, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf3"><p>Maria-Jesus Ortiz-Ruiz, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf4"><p>Robert TePoele, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf5"><p>Olajumoke Adeniji-Popoola, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf6"><p>Gary Box, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf7"><p>Will Court, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf8"><p>Stefanie Czasch, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf9"><p>Samer El Bawab, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf10"><p>Christina Esdar, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf11"><p>Sharon Gowan, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf12"><p>Alexis De Haven Brandon, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf13"><p>Phllip Hewitt, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf14"><p>Stephen M Hobbs, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf15"><p>Wolfgang Kaufmann, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf16"><p>Aur√©lie Mallinger, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf17"><p>Florence Raynaud, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf18"><p>Toby Roe, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf19"><p>Felix Rohdich, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf20"><p>Kai Schiemann, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf21"><p>Stephanie Simon, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf22"><p>Richard Schneider, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf23"><p>Melanie Valenti, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf24"><p>Stefan Weigt, KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf25"><p>Julian Blagg, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf26"><p>Andree Blaukat, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf27"><p>Suzanne A Eccles, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf28"><p>Stefan Hecht, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf29"><p>Klaus Urbahns, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf30"><p>Paul Workman, Current or former employee of The Institute of Cancer Research, which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf31"><p>Dirk Wienke, Current or former employee of Merck KGaA (Darmstadt, Germany), which has a commercial interest in the development of WNT pathway inhibitors.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: In the UK, all animal work was conducted in accordance with National Institute for Cancer Research guidelines, with the research programme and procedures approved by the local Animal Welfare and Ethical Review Boards and subject to UK Government Home Office regulations (Licence PPL 70/7635 &amp; PPL 30/3279). In Germany the animal work was carried out in accordance with the German Law on the Protection of Animals (Article 8a) and the pertaining files at the at the local animal welfare authorities in Darmstadt and Freiburg bear the references DA/375, DA4/1003, DA4/1004 and G13/13 respectively. The studies were designed in accordance with presently valid international study guidelines (e.g. ICH guideline M3 R2) and performed in compliance with animal health and welfare guidelines.The Institute of Cancer Research does not use non-rodent species in research and, where this is deemed essential, requires ethical approval for use by organizations with whom we collaborate. Pharmacokinetic and tolerability analysis of compounds in dogs, necessary for prediction of human pharmacokinetics, was approved by the ICR Animal Welfare and Ethical Review Board. Studies were sponsored and conducted in full compliance with national regulations at an Association for Assessment and Accreditation of Laboratory Animal Care accredited site of Merck Biopharma.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="datasets"><title>Major datasets</title><p/><p>The following datasets were generated:</p><p><related-object content-type="generated-dataset" id="dataro1" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80472" source-id-type="uri"><collab>Clarke PA</collab>, <collab>Ortiz-Ruiz M-J</collab>, <collab>TePoele R</collab>, <collab>Adeniji-Popoola O</collab>, <collab>Box G</collab>, <collab>Court W</collab>, <collab>El Bawab S</collab>, <collab>Esdar C</collab>, <collab>Ewan K</collab>, <collab>Gowan S</collab>, <collab>de Haven Brandon A</collab>, <collab>Hewitt P</collab>, <collab>Hobbs SM</collab>, <collab>Kaufmann W</collab>, <collab>Mallinger A</collab>, <collab>Raynaud F</collab>, <collab>Roe T</collab>, <collab>Rohdich F</collab>, <collab>Schiemann K</collab>, <collab>Simon S</collab>, <collab>Schneider R</collab>, <collab>Valenti M</collab>, <collab>Blagg J</collab>, <collab>Blaukat A</collab>, <collab>Dale T</collab>, <collab>Eccles SA</collab>, <collab>Hecht S</collab>, <collab>Urbahns K</collab>, <collab>Workman P and Wienke D</collab>, <year>2016</year><x>,</x> <source>Assessing the mechanism and therapeutic potential of modulators of the human mediator complex-associated protein kinases</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80472">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE80472</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE80472)</comment></related-object></p><p>The following previously published datasets were used:</p><p><related-object content-type="generated-dataset" id="dataro2" source-id="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65138" source-id-type="uri"><collab>Pelish HE</collab>, <collab>Liau BB</collab>, <collab>Nitulescu II</collab>, <collab>Lemieux ME</collab>, <collab>Shair MD</collab>, <year>2015</year><x>,</x> <source>Effect of cortistatin A (CA) on enhancer occupancy in CA-sensitive and -insensitive human cell lines</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65138">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65138</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE65138)</comment></related-object><related-object content-type="generated-dataset" id="dataro3" source-id="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c2.all.v5.1.symbols.gmt" source-id-type="uri"><collab>Subramanian A</collab>, <collab>Tamayo P</collab>, <collab>Mootha VK</collab>, <collab>Mukherjee S</collab>, <collab>Ebert BL</collab>, <collab>Gillette MA</collab>, <collab>Paulovich A</collab>, <collab>Pomeroy SL</collab>, <collab>Golub TR</collab>, <collab>Lander ES</collab>, <collab>Mesirov JP</collab>, <year>2007</year><x>,</x> <source>Molecular Signatures Database v5.1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c2.all.v5.1.symbols.gmt">http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c2.all.v5.1.symbols.gmt</ext-link><x>,</x> <comment>Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.</comment></related-object><related-object content-type="generated-dataset" id="dataro4" source-id="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c7.all.v5.1.symbols.gmt" source-id-type="uri"><collab>Subramanian A</collab>, <collab>Tamayo P</collab>, <collab>Mootha VK</collab>, <collab>Mukherjee S</collab>, <collab>Ebert BL</collab>, <collab>Gillette MA</collab>, <collab>Paulovich A</collab>, <collab>Pomeroy SL</collab>, <collab>Golub TR</collab>, <collab>Lander ES</collab>, <collab>Mesirov JP</collab>, <year>2007</year><x>,</x> <source>Molecular Signatures Database v5.1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c7.all.v5.1.symbols.gmt">http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c7.all.v5.1.symbols.gmt</ext-link><x>,</x> <comment>Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.</comment></related-object><related-object content-type="generated-dataset" id="dataro5" source-id="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c5.bp.v5.1.symbols.gmt" source-id-type="uri"><collab>Subramanian A</collab>, <collab>Tamayo P</collab>, <collab>Mootha VK</collab>, <collab>Mukherjee S</collab>, <collab>Ebert BL</collab>, <collab>Gillette MA</collab>, <collab>Paulovich A</collab>, <collab>Pomeroy SL</collab>, <collab>Golub TR</collab>, <collab>Lander ES</collab>, <collab>Mesirov JP</collab>, <year>2007</year><x>,</x> <source>Molecular Signatures Database v5.1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c5.bp.v5.1.symbols.gmt">http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c5.bp.v5.1.symbols.gmt</ext-link><x>,</x> <comment>Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.</comment></related-object><related-object content-type="generated-dataset" id="dataro6" source-id="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c3.tft.v5.1.symbols.gmt" source-id-type="uri"><collab>Subramanian A</collab>, <collab>Tamayo P</collab>, <collab>Mootha VK</collab>, <collab>Mukherjee S</collab>, <collab>Ebert BL</collab>, <collab>Gillette MA</collab>, <collab>Paulovich A</collab>, <collab>Pomeroy SL</collab>, <collab>Golub TR</collab>, <collab>Lander ES</collab>, <collab>Mesirov JP</collab>, <year>2007</year><x>,</x> <source>Molecular Signatures Database v5.1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c3.tft.v5.1.symbols.gmt">http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c3.tft.v5.1.symbols.gmt</ext-link><x>,</x> <comment>Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.</comment></related-object><related-object content-type="generated-dataset" id="dataro7" source-id="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c3.tft.v5.1.symbols.gmt" source-id-type="uri"><collab>Subramanian A</collab>, <collab>Tamayo P</collab>, <collab>Mootha VK</collab>, <collab>Mukherjee S</collab>, <collab>Ebert BL</collab>, <collab>Gillette MA</collab>, <collab>Paulovich A</collab>, <collab>Pomeroy SL</collab>, <collab>Golub TR</collab>, <collab>Lander ES</collab>, <collab>Mesirov JP</collab>, <year>2007</year><x>,</x> <source>Molecular Signatures Database v5.1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c3.tft.v5.1.symbols.gmt">http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c3.tft.v5.1.symbols.gmt</ext-link><x>,</x> <comment>Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.</comment></related-object><related-object content-type="generated-dataset" id="dataro8" source-id="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/h.all.v5.1.symbols.gmt" source-id-type="uri"><collab>Subramanian A</collab>, <collab>Tamayo P</collab>, <collab>Mootha VK</collab>, <collab>Mukherjee S</collab>, <collab>Ebert BL</collab>, <collab>Gillette MA</collab>, <collab>Paulovich A</collab>, <collab>Pomeroy SL</collab>, <collab>Golub TR</collab>, <collab>Lander ES</collab>, <collab>Mesirov JP</collab>, <year>2007</year><x>,</x> <source>Molecular Signatures Database v5.1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/h.all.v5.1.symbols.gmt">http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/h.all.v5.1.symbols.gmt</ext-link><x>,</x> <comment>Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.</comment></related-object><related-object content-type="generated-dataset" id="dataro9" source-id="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c6.all.v5.1.symbols.gmt" source-id-type="uri"><collab>Subramanian A</collab>, <collab>Tamayo P</collab>, <collab>Mootha VK</collab>, <collab>Mukherjee S</collab>, <collab>Ebert BL</collab>, <collab>Gillette MA</collab>, <collab>Paulovich A</collab>, <collab>Pomeroy SL</collab>, <collab>Golub TR</collab>, <collab>Lander ES</collab>, <collab>Mesirov JP</collab>, <year>2007</year><x>,</x> <source>Molecular Signatures Database v5.1</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c6.all.v5.1.symbols.gmt">http://software.broadinstitute.org/gsea/msigdb/download_file.jsp?filePath=/resources/msigdb/5.1/c6.all.v5.1.symbols.gmt</ext-link><x>,</x> <comment>Available at the Gene Set Enrichment Analysis site (http://software.broadinstitute.org/gsea/msigdb/). Users are required to register to view the MSigDB gene sets and/or download the GSEA software.</comment></related-object></p></sec><supplementary-material><ext-link xlink:href="elife-20722-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>